RAPT Therapeutics (RAPT) Announced Proposed Offering of $125M Worth of Shares

Go back to RAPT Therapeutics (RAPT) Announced Proposed Offering of $125M Worth of Shares

RAPT Therapeutics (RAPT) Prices 3.79M Common Stock Offering at $33/Sh

June 16, 2021 6:17 AM EDT

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of $33.00 per share. All of the shares of common stock are being offered by RAPT. Gross proceeds to RAPT from the offering are expected to be approximately $125 million,... More

RAPT Therapeutics (RAPT) Adds to Intra-Day Gains Despite Stock Offering; Last Up 23%

June 14, 2021 5:46 PM EDT

RAPT Therapeutics (NASDAQ: RAPT) is adding to its intra-day gains despite announcing a $125 million share stock offering.

Shares are up 22.5% after-hours after gaining 115% intra-day on positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).

... More

Rapt Therapeutics (RAPT) PT Raised to $65 at Wells Fargo

June 14, 2021 2:30 PM EDT

Wells Fargo analyst Yanan Zhu raised the price target on Rapt Therapeutics (NASDAQ: RAPT) to $65.00 (from $30.00) while maintaining a Overweight rating.

... More

Rapt Therapeutics (RAPT) PT Raised to $72 at Roth Capital, Following Clinical Business Update

June 14, 2021 2:21 PM EDT

Roth Capital analyst Zegbeh Jallah raised the price target on Rapt Therapeutics (NASDAQ: RAPT) to $72.00 (from $38.00) while maintaining a Buy rating.

... More

Rapt Therapeutics (RAPT) PT Raised to 'Street High' $71 at Cantor Fitzgerald

June 14, 2021 11:23 AM EDT

Cantor Fitzgerald analyst Alethia Young raised the price target on Rapt Therapeutics (NASDAQ: RAPT) to a "Street High" $71.00 (from $51.00) while maintaining an Overweight rating following today's data.

... More

Increasing unusual option volume: RAPT OR CCXI PARR ITB DS CRSR WEN TD

June 14, 2021 10:21 AM EDT

Increasing unusual option volume: RAPT OR CCXI PARR ITB DS CRSR WEN TD

... More

Pre-Open Stock Movers 06/14: (RAPT) (CRSR) (RIOT) Higher; (ATXI) (RIDE) (RACE) Lower (more...)

June 14, 2021 9:27 AM EDT

Pre-Open Stock Movers:

RAPT Therapeutics (NASDAQ: RAPT) 89% HIGHER; announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).

Avenue Therapeutics, Inc. (NASDAQ: ATXI) 49.4% LOWER; announced that it has received a second Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application seeking... More

RAPT Therapeutics (RAPT) Surges 70% on Positive Early Trial Results

June 14, 2021 8:41 AM EDT

RAPT Therapeutics (NASDAQ: RAPT) surges 70% in pre-open trading after the company announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).

... More

RAPT Therapeutics (RAPT) Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis

June 14, 2021 8:00 AM EDT

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD). After four weeks of treatment, patients with moderate-to-severe AD who received RPT193 showed a 36.3% improvement from baseline in the Eczema Area and Severity Index (EASI) score, a standard measure of disease severity, compared to 17.0% in the placebo group.... More